ADMA Biologics (NASDAQ:ADMA) Shares Gap Down - Time to Sell?

Key Points

• ADMA Biologics shares experienced a significant drop, opening at $15.85 compared to the previous close of $18.54.
• Recent analysts' evaluations show a mix of perspectives, with Raymond James upgrading their price target to $32.00, while Wall Street Zen downgraded the stock to a "sell" rating.
• The company's latest quarterly earnings report indicated a net margin of 45.01% and a revenue growth of 40.2% year-over-year, although it missed expectations for earnings per share.

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $18.54, but opened at $15.85. ADMA Biologics shares last traded at $16.53, with a volume of 2,823,872 shares traded.

Analyst Upgrades and Downgrades

A number of research firms have commented on ADMA. Raymond James Financial raised their price objective on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th.

ADMA Biologics Stock Performance

The stock has a market capitalization of $3.98 billion, a P/E ratio of 19.95 and a beta of 0.38. The company has a quick ratio of 3.36, a current ratio of 6.58 and a debt-to-equity ratio of 0.22. The company has a 50-day moving average price of $18.76 and a two-hundred day moving average price of $18.81.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The business had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. During the same period in the prior year, the business posted $0.08 EPS. ADMA Biologics's quarterly revenue was up 40.2% on a year-over-year basis. Equities analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 20,000 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the transaction, the director directly owned 94,830 shares of the company's stock, valued at $1,987,636.80. The trade was a 17.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jerrold B. Grossman sold 10,000 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the transaction, the director directly owned 478,194 shares of the company's stock, valued at approximately $10,190,314.14. This trade represents a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 464,621 shares of company stock valued at $9,644,269 over the last three months. 3.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ADMA Biologics

Institutional investors and hedge funds have recently modified their holdings of the stock. Skandinaviska Enskilda Banken AB publ bought a new position in ADMA Biologics during the 1st quarter valued at approximately $35,000. SVB Wealth LLC bought a new position in shares of ADMA Biologics during the first quarter valued at $35,000. Cullen Frost Bankers Inc. raised its position in shares of ADMA Biologics by 112.5% in the 2nd quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company's stock worth $37,000 after purchasing an additional 1,081 shares during the last quarter. Toth Financial Advisory Corp boosted its stake in ADMA Biologics by 1,081.6% in the 2nd quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company's stock worth $46,000 after purchasing an additional 2,293 shares in the last quarter. Finally, Ameritas Advisory Services LLC purchased a new stake in ADMA Biologics during the 2nd quarter valued at about $46,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.